Formulary Management of Drugs for Cancer-Associated Hypercalcaemia

PharmacoEconomics

Volumn 9, Issue 1, 1996, Pages 39-50

  Gallacher, Stephen J ^a,b  

^a SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; CORTICOSTEROID; ETIDRONIC ACID; GALLIUM NITRATE; MITHRAMYCIN; OCTREOTIDE; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PHOSPHATE;

CANCER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FORMULARY; EXTRACELLULAR SPACE; FEVER; HUMAN; HYPERCALCEMIA; LIVER DYSFUNCTION; NEPHROTOXICITY; OSTEOLYSIS; PRIORITY JOURNAL; REHYDRATION; REVIEW; SQUAMOUS CELL CARCINOMA; VOMITING;

COST-BENEFIT ANALYSIS; FORMULARIES, HOSPITAL; HUMANS; HYPERCALCEMIA; NEOPLASMS;

EID: 0030058738     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609010-00005     Document Type: Review

References (106)

1. Fisken RA, Heath DA, Bold AM. Hypercalcaemia - a hospital survey. Q J Med 1980; 49: 405-18
2. Mundy GR, editor. Calcium homeostasis: hypercalcaemia and hypocalcaemia. London: Martin Dunitz, 1989: 54
3. McKay C, Furman L. Hypercalcemia complicating childhood malignancies. Cancer 1993; 72: 256-60
4. Mundy GR, Ibbotson KJ, D'Souza SM, et al. The hypercalcemia of cancer: clinical implications and pathogenic mechanisms. N Engl J Med 1984; 310: 1718-27
5. Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364-7
6. Gallacher SJ, Farquharson MA, Fraser WD, et al. Coincidental occurrence of primary hyperparathyroidism and cancer-associated hypercalcaemia in a middle-aged man. Clin Endocrinol 1993; 38: 433-7
7. Mundy GR, Raisz LG, Cooper RA, et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974; 291: 1041-6
8. Gallacher SJ. Pathogenesis and management of cancer-associated hypercalcaemia. Cancer J 1992; 5: 73-7
9. Suva LJ, Winslow GA, Wettenhall REH, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression. Science 1987; 237: 893-6
10. Kemp BE, Moseley JM, Rodda CP, et al. Parathyroid hormone-related protein of malignancy: active synthetic fragments. Science 1987; 238: 1568-70
11. Besarab A, Caro JF. Mechanisms of hypercalcemia in malignancy. Cancer 1978; 41: 2276-85
12. Mundy GR, Martin TJ. The hypercalcemia of cancer: pathogenesis and management. Metabolism 1982; 31: 1247-77
13. Walser M. Calcium clearance as a function of sodium clearance in the dog. Am J Physiol 1961; 200: 1099-104
14. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981; 50: 473-81
15. Fleisch H. Chemistry and mechanism of action of bisphosphonates. In: Garattini S, editor. Bone resorption, metastasis and diphosphonates. New York: Raven Press, 1985
16. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhihit hydroxyapatite dissolution in vitro and bone resorption in tissue culture in vivo. Science 1969; 165: 1262-4
17. Ralston SH, Gardner MD, Dryburgh FJ, et al. Comparison of aminohydroxypropylidene diphosphonate, mithramycin and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet 1985; 2: 907-10
18. Wallach S. Treatment of Paget's disease. Adv Intern Med 1982; 27: 1-43
19. Singer FR, Ritch PS, Lad TE, et al. Treatment of hypercalcemia of malignancy with intravenous etidronate. Arch Intern Med 1991; 151: 471-6
20. Ringenberg QS, Ritch PS. Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients. Clin Ther 1987; 9: 318-25
21. Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; 2: 1180-2
22. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumour induced hypercalcaemic and metastatic bone disease. Drugs 1991; 42: 919-44
23. Chapuy MC, Meunier PJ, Alexandre CM, et al. Effects of dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. J Clin Invest 1980; 65: 1243-7
24. Douglas DL, Russell RGG, Preston CJ, et al. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1980; 1: 1043-7
25. Rotstein S, Glas U, Eriksson M, et al. Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases - a prospective randomised placebo controlled multicentre study. Eur J Cancer 1992; 28A: 890-3
26. Adami S, Bolizicco GP, Rtizo A, et al. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner 1987; 2: 395-404
27. Ziegler R, Scharla SH. Treatment of tumor hypercalcemia with clodronate. Recent Results Cancer Res 1989; 116: 46-53
28. Urwin GH, Yates AJP, Gray RES, et al. Treatment of hypercalcaemia of malignancy with clodronate. Bone 1987; 8 Suppl. 1: S43-51
29. Kanis JA, McCloskey EV, Paterson AHG. Use of diphosphonates in hypercalcaemia due to malignancy. Lancet 1990; 335: 170-1
30. O'Rourke NP, McCloskey EV, Vasilkaran S, et al. Effective treatment of hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993; 67: 560-3
31. Percival RC, Paterson AD, Yates AJP, et al. Treatment of malignant hypercalcaemia with clodronate. Br J Cancer 1985; 51: 665-9
32. Rastad J, Benson L, Johansson H, et al. Clodronate treatment in patients with malignancy-associated hypercalcaemia. Acta Med Scand 1987; 221: 489-94
33. Jacobs TP, Siris ES, Bilizikian JP, et al. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. Ann Intern Med 1981; 94: 312-6
34. Bounameaux HM, Sheifferli J, Montani J-P, et al. Renal failure associated with intravenous diphosphonates [letter]. Lancet 1983; 1: 471
35. Mian M, Beghe F, Caprio A, et al. Tolerability and safety of clodronate therapy in bone diseases. Int J Clin Pharmacol Res 1991; 11: 107-14
36. Plosker GL, Goa KL. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994; 47: 945-82
37. Ralston SH, Alzaid AA, Gallacher SJ, et al. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. Q J Med 1988; 69 (258): 825-34
38. Thiebaud D, Jaeger P, Burckhardt P. Response to re-treatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD); respective role of kidney and bone. J Bone Miner Res 1990; 5: 221-6
39. Lowik CWGM, van der Pluijm G, van der Wee-Pals LJA, et al. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasls: the effect of a bisphosphonate. J Bone Miner Res 1988; 3: 185-92
40. 2MDP on bone in the rat: in vivo and in vitro studies. Metab Bone Dis Rel Res 1980; 2: 381-7
41. Van Breukelen FJM, Bijvoet OLM, Frijlink WB, et al. Efficacy of aminohydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium. Calcif Tissue Int 1982; 34: 321-7
42. Sleeboom HP, Bijvoet OLM, Van Oosteroom AT, et al. Comparison of intravenous 3-amino-1,1-hydroxypropylidene bisphosphonate and volume repletion in tumour induced hypercalcaemia. Lancet 1983; 1: 239-43
43. Cantwell BMJ, Harris AL. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate in hypercalcaemia caused by cancer. BMJ 1987; 294: 467-9
44. Yates AJP, Jerwis JG, Murray RML, et al. A comparison of single and multiple infusions of 3-amino-1,1-hydroxypropylidene bisphosphonate (APD) in the treatment of hypercalcaemia of malignancy. Aust NZ J Med 1987; 17: 387-91
45. Thiebaud D, Jaeger PH, Jacquet AF, et al. A single day treatment of tumor induced hypercalcemia by intravenous aminohydroxypropylidene bisphosphonate. J Bone Miner Res 1986; 1: 555-62
46. Morton AR, Cantrill JA, Craig AE, et al. Single dose versus daily intravenous aminohydroxypropylidene bisphosphonate (APD) for the hypercalcaemia of malignancy. BMJ 1988; 296: 811-4
47. Gucalp R, Theriault R, Gill I, et al. Treatment of cancer-associated hypercalcemia: double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 1994; 154: 1935-44
48. Sawyer N, Newstead C, Drummond A, et al. Fast (4-h) or slow (24-h) infusions of pamidronate (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Bone Miner 1990; 9: 122-8
49. Dodwell DJ, Howell A, Morton AR, et al. Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia. Postgrad Med J 1992; 68: 434-9
50. Thiebaud D, Jaeger P, Jaquet AF, et al. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 1988; 6: 762-8
51. Purohit OP, Anthony C, Owen J, et al. Comparison of single infusion of pamidronate or clodronate for the treatment of malignant hypercalcaemia [abstract]. Br J Cancer 1994; 70 Suppl. XXII: P41
52. Nussbaum SR, Younger J, Vandepol CJ, et al. Single dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90mg doses. Am J Med 1993; 95: 297-304
53. Gurney H, Kefford R, Stuart-Harris R. Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy. Lancet 1989; 2: 241-4
54. Gallacher SJ, Fraser WD, Logue FC, et al. Factors predicting the acute effect of pamidronate on serum calcium in hypercalcaemia of malignancy. Calcif Tissue Int 1992; 51: 419-23
55. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993; 341: 1611-3
56. Body JJ, Dumon JC, Thirion M, et al. Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence of the response to bisphosphonate and changes after therapy. J Bone Miner Res 1993; 8: 701-6
57. Wimalawansa SJ. Significance of plasma PTHrP in patients with hypercalcemia of malignancy treated with bisphosphonates. Cancer 1994; 73: 2223-30
58. Gallacher SJ, Ralston SH, Patel U, et al. Side effects of pamidronate. Lancet 1989; 2: 42-3
59. Nussbaum SR, Warrell RP, Rude R, et al. Dose response study of alendronate sodium for treatment of cancer-associated hypercalcemia. J Clin Oncol 1993; 11: 1618-23
60. Zysset E, Ammann P, Jenzer A, et al. Comparison of a rapid (2-h) and a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone Miner 1992; 18: 237-49
61. Bickerstaff DR, O'Doherty DP, McCloskey EV, et al. Effects of amino-butylidene diphosphonate in hypercalcaemia due to malignancy. Bone 1991; 12: 17-20
62. Reginster JY, Deroisy R, Denis D, et al. Prevention of post-menopausal bone loss by tiludronate. Lancet 1989; 2: 1469-71
63. Dumon JC, Magritte A, Body JJ. Efficacy and safety of the bisphosphonate tiludronate in the treatment of tumor-associated hypercalcemia. Bone Miner 1991; 15: 257-66
64. Warrell RP, Murphy WK, Schuman P, et al. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1991; 9: 1467-75
65. Rizzoli R, Buchs B, Bonjour JP. Effect of a single infusion of alendronate in malignant hypercalcemia: dose dependency and comparison with clodronate. Int J Cancer 1992; 50: 706-12
66. Ostenstad B, Andersen OK. Disodium pamidronate versus mithramycin in the management of tumour-associated hypercalcaemia. Acta Oncol 1992; 31: 861-4
67. Thiebaud D, Jacquet AF, Burckhardt P. Fast and effective treatment of malignant hypercalcemia: combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate. Arch Intern Med 1990; 150: 2125-8
68. Fateri S, Singer FR, Rude RK. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 1992; 50: 107-9
69. Copp DH, Cameron EC, Cheyney EC, et al. Evidence for calcitonin - a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962; 70: 638-49
70. Johnston C, Deiss WP. The inhibitory effect of thyrocalcitonin on calcium release in vivo and on bone metabolism in vitro. Endocrinology 1966; 78: 1139-43
71. Hosking DJ, Gilson D. Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Q J Med 1984; 211: 359-68
72. West TET, Joffe M, Sinclair L, et al. Treatment of hypercalcaemia with calcitonin. Lancet 1971; 1: 675-8
73. Werner JA, Gorton SJ, Raisz LG. Escape from inhibition of re orption in cultures of fetal bone treated with calcitonin and parathyroid hormone. Endocrinology 1972; 90: 752-9
74. Au WYW. Calcitonin treatment of hypercalcemia due to parathyroid carcinoma - synergistic effect of prednisone on long term treatment of hypercalcemia. Arch Intern Med 1975; 135: 1594-7
75. Bower M, Stein RC, Hedley A, et al. The use of nasal calcitonin spray in the treatment of hypercalcemia of malignancy. Cancer Chemother Pharmacol 1991; 28: 311-2
76. Dumon JC, Magritte A, Body JJ. Nasal human calcitonin for tumor-induced hypercalcemia. Calcif Tissue Int 1992; 51: 18-9
77. Hosking DJ, Bijvoet OLM. Therapeutic uses of calcitonin. In: Parsons JA, editor. Endocrinology of calcium metabolism. New York: Raven Press, 1982: 485-535
78. Mundy GR, Wilkinson R, Heath DA. Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med 1983; 74: 421-3
79. Strumpf M, Kowalski MA, Mundy GR. Effect of corticosteroids on osteoclast activating factor. J Lab Clin Med 1978; 92: 772-8
80. Thallasinos NC, Joplin GF. Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease. Lancet 1970; 2: 537-9
81. Percival RC, Yates AJP, Gray RES, et al. Role of glucocorticoids in the management of malignant hypercalcaemia. BMJ 1984; 289: 287
82. Anderson JC, Dent E, Harper C, et al. Effect of cortisone on calcium metabolism in sarcoidosis with hypercalcaemia: possible antagonistic action of cortisone and vitamin D. Lancet 1954; 2: 720-4
83. Kiang DT, Loken MK, Kennedy BJ. Mechanism of the hypocalcemic effect of mithramycin. J Clin Endocrinol Metab 1979; 48: 341-4
84. Yarbro JW, Kennedy BJ, Barnum CP. Mithramycin inhibition of ribonucleic acid synthesis. Cancer Res 1966; 26: 36-9
85. Perlia CP, Gubisch NJ, Wolter J, et al. Mithramycin treatment of hypercalcemia. Cancer 1970; 25: 389-94
86. Kennedy BJ. Metabolic and toxic effects of mithramycin during tumor therapy. Am J Med 1970; 49: 494-503
87. Ryan WG, Schwartz TB, Northrop G. Experiences in the treatment of Paget's disease of bone with mithramycin. JAMA 1970; 213: 1153-7
88. Monto RW, Talley RW, Caldwell MJ, et al. Observations on the mechanisms of haemorrhagic toxicity in mithramycin (NSC-24559) therapy. Cancer Res 1969; 29: 697-704
89. Warrell RP, Bockman RS, Coonley CJ, et al. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for calcium-related hypercalcemia. J Clin Invest 1984; 73: 487-90
90. Bockman RS, Repo MA, Warrell RP, et al. Gallium localization in bone: micron range resolution using synchrotron X-ray microscopy. Proc Natl Acad Sci USA 1990; 87: 4149-53
91. Warrell RP, Alcock NW, Bockman RS. Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases. J Clin Oncol 1987; 5: 292-8
92. Warrell RP, Israel R, Frisone M, et al. Gallium nitrate for acute treatment of cancer-related hypercalcemia: a randomized double-blind comparison to calcitonin. Ann Intern Med 1988; 108: 669-74
93. Matkovic V, Apseloff G, Shepard DR, et al. Use of gallium to treat Pagel's disease of bone: a pilot study. Lancet 1990; 335: 72-5
94. Bulger HA, Dixon HH, Barr DP, et al. Functional pathology of hyperparathyroidism. J Clin Invest 1930; 9: 143-90
95. Goldsmith RS, Ingbar SH. Inorganic phosphate treatment of hypercalcemia of diverse etiologies. N Engl J Med 1996; 274: 1-7
96. Breur RI, Lebauer J. Caution in the use of phosphates in the treatment of severe hypercalcemia. J Clin Endocrinol Metab 1967; 27: 695-8
97. Carew RW, Schmitt GW, Kopald HH, et al. Massive extraskeletal calcification during phosphate treatment of hypercalcemia. Arch Intern Med 1968; 122: 150-5
98. Shackney S, Hasson J. Precipitous fall in serum calcium and acute renal failure after intravenous phosphate therapy for hypercalcemia: report of two cases. Ann Intern Med 1967; 66: 906-16
99. Kukreja SC, D'Anza JJ, Wimbiscus SA, et al. Inactivation by plasma may be responsible for the lack of efficacy of parathyroid hormone antagonists in hypercalcemia of malignancy. Endocrinology 1994; 134: 2184-8
100. Haq M, Kremer R, Goltzman D, et al. A vitamin D analogue (EB 1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia. J Clin Invest 1993; 91: 2416-22
101. Peckerstorfer M, Schilling T, Blind E, et al. Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 1994; 78: 1268-70
102. Harrison M, James N, Broadley K, et al. Somatostatin analogue treatment for malignant hypercalcaemia. BMJ 1990; 300: 1313-4
103. Wynick D, Ratcliffe WA, Heath DA, et al. Treatment of a malignant pancreatic endocrine tumour secreting parathyroid hormone-related protein. BMJ 1990; 300: 1314-5
104. Ralston SH, Gallacher SJ, Patel U, et al. Cancer-associated hypercalcemia: morbidity and mortality in 126 treated patients. Ann Intern Med 1990; 112: 499-504
105. Boisaubin EV, Lynch GR, Dresser R. Hypercalcemia of advanced malignancy: decision making and quality of death. Am J Med Sci 1991; 305: 314-8
106. Biermann WA, Cantor RI, Fellin FM, et al. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone 1991; 12 Suppl. 1: S37-42